Search Results - "Vredenburg, Michael"

Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia by Jain, Shivi, Gernsheimer, Terry, Kolodny, Scott, Bernheisel, Chelsea, Vredenburg, Michael, Panch, Sandhya R.

“…Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA) that was approved in the US in 2019 for treatment of chronic immune thrombocytopenia (ITP)…”
Get full text

PB2622: A PROSPECTIVE, OPEN‐LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM by Kolodny, Scott, Vredenburg, Michael, Zhang, Jessica, Jamieson, Brian

Get full text

Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study by Oladapo, Abiola, Kolodny, Scott, Vredenburg, Michael, Swallow, Elyse, Goldschmidt, Debbie, Sarathy, Kirthana, Lopez, Priscilla, Maitland, Hillary, Yee, John

“…Background: Thrombopoietin-receptor agonists (TPO-RAs) are used to treat immune thrombocytopenia (ITP), a disorder characterized by prolonged low platelet…”
Get full text

Effects of Orally Active Taxanes on P-Glycoprotein Modulation and Colon and Breast Carcinoma Drug Resistance by Vredenburg, Michael R., Ojima, Iwao, Veith, Jean, Pera, Paula, Kee, Kristin, Cabral, Fernando, Sharma, Amarnath, Kanter, Peter, Greco, William R., Bernacki, Ralph J.

“…Background: The taxane paclitaxel (Taxol) is often of limited efficacy in chemotherapeutic regimens because some cancer cells express high levels of the efflux…”
Get full text

Characterization of Thromboembolic Events Occurring during the Avatrombopag Immune Thrombocytopenia (ITP) Clinical Development Program by Piatek, Caroline I., Jamieson, Brian, Vredenburg, Michael

“…Background: ITP management often requires subsequent therapy beyond current first line treatments (corticosteroids or intravenous immunoglobulin). The use of…”
Get full text

The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells by Brooks, Tracy A, O'Loughlin, Kieran L, Minderman, Hans, Bundy, Brian N, Ford, Laurie A, Vredenburg, Michael R, Bernacki, Ralph J, Priebe, Waldemar, Baer, Maria R

“…The synthetic 4'-O-benzylated doxorubicin analog WP744 was designed to abrogate transport by the multidrug resistance (MDR)-associated ATP-binding cassette…”
Get full text

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study by Al‐Samkari, Hanny, Jiang, Debbie, Gernsheimer, Terry, Liebman, Howard, Lee, Susie, Wojdyla, Matthew, Vredenburg, Michael, Cuker, Adam

“…Summary Patients with immune thrombocytopenia (ITP) may respond to one thrombopoietin receptor agonist (TPO‐RA) but not another. Limited data are available…”
Get full text

DELAYED DIAGNOSIS OF AMYLOIDOSIS AS A CAUSE OF OUT-OF-HOSPITAL CARDIAC ARREST by Kurecka, Patrick, Akram, Mahrukh F., Cameron, David, Vredenburg, Michael C., McNamara, Richard F.

Get full text

Interim Analysis of Treatment Satisfaction from a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag or Romiplostim to Avatrombopag by Tarantino, Michael D., Kolodny, Scott, Zhang, Jessica, Jamieson, Brian, Vredenburg, Michael

“…Background: Recently, the Thrombopoietin-Receptor Agonist (TPO-RA) Patient experience survey (TRAPeze) determined that the characteristics which influence…”
Get full text

Interim Analysis of Platelet Response in a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) by Tarantino, Michael D., Kolodny, Scott, Zhang, Jessica, Jamieson, Brian, Vredenburg, Michael

“…Background: Three thrombopoietin receptor agonists (TPO-RAs) [eltrombopag, romiplostim, and avatrombopag] are currently approved in the United States (US) and…”
Get full text

Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib in the United States by Marrone, Michael, Geller, Robert, Oladapo, Abiola, Suthar, Purvi, Vasudevan, Anupama, Vredenburg, Michael, Zeng, Jia, Rampal, Raajit, Mascarenhas, John

“…6579 Background: Pacritinib (PAC), a JAK1 sparing JAK2/IRAK1/ACVR1 inhibitor, has shown clinically significant activity in spleen volume and symptom reduction…”
Get full text

Platelet Response to Avatrombopag in Patients with Chronic Immune Thrombocytopenia: Additional Analyses from a Phase 3 Study and Its Extension by Nagalla, Srikanth, Vredenburg, Michael, Tian, Wei, Allen, Lee F.

“…Background: Avatrombopag (AVA) is a novel, oral thrombopoietin receptor agonist (TPO-RA) recently FDA approved for the treatment of chronic immune…”
Get full text

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Study Design by Nagalla, Srikanth, Chaturvedi, Shruti, Levy, Moshe, Kolodny, Scott, Oladapo, Abiola, Bernheisel, Chelsea, Jamieson, Brian, Goldschmidt, Debbie, Swallow, Elyse, Greatsinger, Ali, Vredenburg, Michael

“…Background: Thrombopoietin-receptor agonists (TPO-RAs) are used in the treatment of chronic immune thrombocytopenia (ITP), a disorder characterized by…”
Get full text

Durability of Initial Platelet Count Response in Patients Treated with Avatrombopag for Immune Thrombocytopenia (ITP): Post-Hoc Results from a Phase 3 Clinical Study by Jain, Shivi, Wojdyla, Matthew, Vredenburg, Michael, Jamieson, Brian, Gernsheimer, Terry B.

“…Background: The clinical management of ITP has been evolving. Thrombopoietin receptor agonists (TPO-RAs) have become widely utilized as subsequent treatments,…”
Get full text

Efficacy Analyses from the Immune Thrombocytopenia (ITP) Clinical Development Program for Avatrombopag: Comparisons with Placebo and Eltrombopag by Tarantino, Michael D, Vredenburg, Michael, Tian, Wei, Jamieson, Brian, Patel, Kashyap B

“…Background: Management of ITP following failure of 1st line therapy, such as corticosteroids or intravenous immunoglobulin, continues to evolve. The use of…”
Get full text

Consistent Efficacy Demonstrated By Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment by Blinder, Morey, Vredenburg, Michael, Tian, Wei, Jamieson, Brian, McCrae, Keith R

“…▪ Background: Clinical management of ITP depends on both disease severity and risk of bleeding. Treatment typically is considered when platelet counts (PC)…”
Get full text

Avatrombopag Treatment Response in Patients with Immune Thrombocytopenia: A Real-World Evidence Study by Oladapo, Abiola, Kolodny, Scott, Vredenburg, Michael, Jamieson, Brian, Swallow, Elyse, Goldschmidt, Debbie, Zichlin, Miriam L., Davidson, Mikhail, Yu, Louise, Yee, John

Get full text

Real-World Demographic and Clinical Characteristics of Patients Initiating Avatrombopag in the US: The Real-AVA Study by Kolodny, Scott, Oladapo, Abiola, Vredenburg, Michael, Jamieson, Brian, Swallow, Elyse, Goldschmidt, Debbie, Zichlin, Miriam L., Lopez, Priscilla, Davidson, Mikhail, Yee, John

Get full text

MPN-386 Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With Pacritinib in the United States by Marrone, Michael, Geller, Robert, Oladapo, Abiola, Suthar, Purvi, Vasudevan, Anupama, Vredenburg, Michael, Zeng, Jia, Rampal, Raajit, Mascarenhas, John

“…Pacritinib, a JAK1 sparing JAK2/IRAK1/ACVR1 inhibitor, has shown clinically significant activity in spleen volume and symptom reduction in thrombocytopenic…”
Get full text

Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With Pacritinib in the United States by Marrone, Michael, Geller, Robert, Oladapo, Abiola, Suthar, Purvi, Vasudevan, Anupama, Vredenburg, Michael, Zeng, Jia, Rampal, Raajit, Mascarenhas, John

Get full text